ÇÏ¿¬Á¤
¼Ò
¼Ó
: ºÐ´çÂ÷º´¿ø
Àü¹®ºÐ¾ß : °£Àå, °£¾Ï
Á÷
ˤ
: Á¶±³¼ö
¸Þ
ÀÏ
:
ºñ°ø°³
Àü
È
:
1577-4488
ÆÑ
½º
:
ÁÖ
¼Ò
:
°æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
ȨÆäÀÌÁö:
ÅǸ޴º
ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£
±¸ºÐ
Á¦¸ñ
´Ù¿î·Îµå
24
ÇØ¿Ü
, Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate, Sci. Rep., 10 (2020) 13537.
23
ÇØ¿Ü
Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib, Hepatol. Int., (2020).
22
ÇØ¿Ü
High body mass index hinders fibrosis improvement in patients receiving long-term tenofovir therapy in hepatitis B virus-related cirrhosis, J. Viral Hepat., (2020).
21
ÇØ¿Ü
Decrease in waist-to-hip ratio reduced the development of chronic kidney disease in non-obese non-alcoholic fatty liver disease, Sci. Rep., 10 (2020) 8996.
20
ÇØ¿Ü
A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy, Cancers (Basel), 12 (2020).
19
ÇØ¿Ü
, Induction of Lysosome-associated Protein Transmembrane 4 Beta via Sulfatase 2 Enhances Autophagic Flux in Liver Cancer Cells, Hepatology communications, 3 (2019) 1520-1543.
18
ÇØ¿Ü
Circulating tumor cells are associated with poor outcomes in early-stage hepatocellular carcinoma: a prospective study, Hepatol. Int., 13 (2019) 726-735.
17
ÇØ¿Ü
Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy, Eur. J. Gastroenterol. Hepatol., (2019).
16
ÇØ¿Ü
Validation of the Liver Disease Quality of Life Instrument 1.0 in Patients with Chronic Hepatitis B: A Prospective Study, Journal of clinical medicine, 8 (2019).
15
ÇØ¿Ü
Development of a New Nomogram Including Neutrophil-to-Lymphocyte Ratio to Predict Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization, Cancers (Basel), 11 (2019).
1
2
3
Copyright ¨Ï chamc, All rights reserved.
ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à
Àüȹ®ÀÇ
°³²Â÷º´¿ø 02.3468.3000
ºÐ´çÂ÷º´¿ø 031.780.5000
Â÷¿ò 02.3015.5300
±¸¹ÌÂ÷º´¿ø 054.450.9700
´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
°³²°ÇÁø¼¾ÅÍ 02.2191.3900
ºÐ´çÁ¾ÇÕ°Ç°ÁõÁø¼¾ÅÍ 031.780.5940
½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729